natgillin/translations-raw huggingface dataset:
Forbedring af HAQ-DI-score fra baseline blev opretholdt til og med uge 52 og uge 100.
Improvement in HAQ- DI score from baseline was maintained through Weeks 52 and 100.
Forbedring af kronisk
CKD improvement by
Forbedring af lungefunktionen blev understøttet af et reduceret forbrug af salmeterol i ugerne 1-12 (-0,4 pust pr. dag (95 % CI: -0,7; -0,2, p < 0,001) og -0,3 pust pr. dag (95 % CI: -0,5; -0,1, p = 0,003)), sammenlignet med placebo plus FF/VI.
Improvements in lung function were supported with reductions in use of salbutamol over Weeks 1-12 (-0.4 puffs per day (95% CI -0.7, -0.2, p<0.001) and -0.3 puffs per day (95% CI -0.5, -0.1, p=0.003)) compared to
Forbedring af målene for livskvalitet, reduktion i sygdomsrelateret hospitaliseringer og brug af kortikosteroid sås for infliximab-vedligeholdelsesgrupperne sammenlignet med placebo- vedligeholdelsesgruppen ved ugerne 30 og 54.
Improvements in quality of life measures, a reduction in disease-related hospitalizations and corticosteroid use were seen in the infliximab maintenance groups compared with the placebo maintenance group at weeks 30 and 54.
Forbedring af surrogatmarkører for betacellefunktionen, inklusive HOMA-β (homøostatisk modelvurdering af β- cellefunktionen), proinsulin/insulin-ratio samt resultater fra en frequently sampled meal tolerance test blev observeret.
Improvements in surrogate markers of beta cell function, including HOMA-β (Homeostasis Model Assessment-β), proinsulin to insulin ratio, and measures of beta cell responsiveness from the frequently-sampled meal tolerance test were observed.
Forbedring af symptomer på opioidinduceret obstipation
OIC symptom improvement
Forbedring blev defineret som en reduktion fra baseline på mindst to eller flere points i Knodell’s nekro-inflammatoriske score uden nogen samtidig forværring i Knodell’s fibrosescore.
Improvement was defined as a reduction from baseline of two points or more in the Knodell necro-inflammatory score with no concurrent worsening in the Knodell fibrosis score.
Forbedring fra baseline i HAQ gennemsnitligt over tid fra uge 30 til uge 54c
Improvement from baseline in HAQ averaged over time from week 30 to week 54c
Forbedring i
Improved
Forbedring i antallet af led med aktiv artrit blev opretholdt i den åbne del af studiet i 52 uger.
Improvement in number of active joints with arthritis was maintained during the OL period through Week 52 of the study.
Forbedring i beskyttelsesgrad (95 % CI)b
Improved Efficacy (95% CI)b
Forbedring i beskyttelsesgrad (95% CI)b
Improved Efficacy (95% CI)b
Forbedring i forhold til baseline for pædiatriske ACR-komponenter ved uge 16a
Improvements from baseline in ACR Ped components at week 16a
Forbedring i fysisk funktion blev målt ved HAQ-DI (Health Assessment Questionnaire Disability Index) i studie II, III, IV, V og VI samt et modificeret HAQ-DI i studie I. I studie SC-I var forbedring fra baseline målt ved HAQ-DI ved måned 6 og over tid den samme ved subkutan og intravenøs administration.
Improvement in physical function was measured by the Health Assessment Questionnaire Disability Index (HAQ-DI) in Studies II, III, IV, V, and VI and the modified HAQ-DI in Study I. In Study SC-I, improvement from baseline as measured by HAQ-DI at 6 months and over time was similar between subcutaneous and intravenous administration.
Forbedring i fysisk funktion blev målt ved HAQ-DI (Health Assessment Questionnaire Disability Index) i studie II, III, IV, V og VI samt et modificeret HAQ-DI i studie I. Resultater fra studie II, III og VI angives i Tabel 7.
Improvement in physical function was measured by the Health Assessment Questionnaire Disability Index (HAQ-DI) in Studies II, III, IV, V, and VI and the modified HAQ-DI in Study I. The results from Studies II, III, and VI are shown in Table 7.
Forbedring i HbA1C var ikke påvirket af køn, etnicitet, alder, diabetesvarighed (<10 år og ≥10 år), HbA1c-værdi ved baseline (<8 % eller ≥8 %) eller body mass index (BMI).
Improvement in HbA1C was not affected by, gender, ethnicity, age, diabetes duration (<10 years and ≥10 years), HbA1c value at baseline (<8% or ≥8%) or baseline body mass index (BMI).
Forbedring i Ishak fibrose-score
Ishak fibrosis score improvement
Forbedring i surrogatmarkører for betacellefunktionen, inklusive HOMA-β (homøostatisk modelvurdering af β- cellefunktionen), proinsulin/insulin-ratio samt resultater fra en frequently sampled meal tolerance test blev observeret.
Improvements in surrogate markers of beta cell function, including HOMA-β (Homeostasis Model Assessment-β), proinsulin to insulin ratio, and measures of beta cell responsiveness from the frequently-sampled meal tolerance test were observed.
Forbedring over placebo
Improvement over placebo
Forbedring på
Gain of
Forbedring på 50 %
50% improvement
Forbedring ≥ 90% i lægens samlede vurdering
Improvement ≥ 90% in Physician’s Global Evaluation
Forbedring  90% i lægens samlede vurdering
Improvement  90% in Physician’s Global Evaluation
forbedringd
improvementd
Forbedringen af den fysiske formåen og HRQol blev opretholdt over den 2-årige åbne forlængelse til RA-I.
Improvements in physical function and HRQoL were maintained through 2 years in the open-label extension to RA-I.
Forbedringen blev fastholdt i en opfølgningsperiode på op til 60 måneder.
The improvement was maintained over a follow-up period of up to 60 months.
Forbedringen i den totale international prostate symptom score med tadalafil 5 mg i de fire studier var -4,8, -5,6, -6,1 og -6,3 sammenlignet med -2,2, - 3,6, -3,8 og -4,2 for placebo.
The improvement in the total international prostate symptom score with tadalafil 5 mg in the four studies were -4.8, -5.6, -6.1 and -6.3 compared to -2.2, -3.6, -3.8 and -4.2 with placebo.
Forbedringen i HbA1c fra baseline blev opretholdt i gruppen, der fik saxagliptin som tillæg til insulin, sammenlignet med gruppen, der fik placebo som tillæg til insulin med eller uden metformin til uge 52.
Improvements from baseline HbA1c were sustained in the saxagliptin add-on to insulin group compared to the placebo add-on to insulin group with or without metformin at Week 52.
Forbedringer blev observeret i UPDRS-score del I – IV.
Improvements were seen in UPDRS Parts I - IV scores.
Forbedringer eller stabilisering blev set i Child-Pugh-Turcotte’s score.
Improvements or stabilisation were seen in Child- Pugh-Turcotte score.
Forbedringer i BMD blev bemærket 96 uger efter skift til Genvoya fra et TDF-baseret regime, sammenlignet med regimet, der bibeholder TDF.
Improvements in BMD were noted at 96 weeks after switching to Genvoya from a TDF-containing regimen compared to maintaining the TDF-containing regimen.
Forbedringer i de vigtigste parametre for sygdomsaktivitet blev observeret ved den første evaluering (uge 4) efter Simponi-administration og ved uge 24.
These changes were observed at the first assessment (week 4) after the initial Simponi administration and were generally maintained through week 24.
Forbedringer i den tid, patienterne levede, uden at deres sygdom forværredes, når de blev behandlet med Opdivo og ipilimumab, sammenlignet med Opdivo alene, blev kun konstateret hos de patienter, hvis kræftceller producerede et lavt antal PD-L1.
Improvements in the time patients lived without their disease getting worse when treated with Opdivo plus ipilimumab relative to Opdivo used on its own were only seen for patients whose cancer cells produced low levels of PD-L1.
Forbedringer i DLQI blev opretholdt til og med uge 52 hos personer, der igen blev randomiseret til apremilast efter uge 32 (tabel 5).
Improvements in DLQI were maintained through Week 52 in subjects who were re-randomized to apremilast at Week 32 (Table 5).
Forbedringer i HAQ-DI- score sås uanset tidligere eksponering for anti-TNFα.
Improvements in HAQ-DI scores were seen regardless of previous anti-TNFα exposure.
Forbedringer i HAQ-DI-scores blev opretholdt efter uge 24.
Improvement in HAQ-DI scores was maintained at Week 24.
Forbedringerne blev generelt opretholdt hos personer, der igen blev randomiseret til Otezla fra uge 32 til og med uge 52 (tabel 5).
The improvements were generally maintained in subjects who were re-randomized to Otezla at Week 32 through Week 52 (Table 5).
Forbedringerne i blodtrykket blev opretholdt i 52 uger.
Improvements in blood pressure were maintained through 52 weeks.
Forbedringerne i FEV1 med Colobreathe blev anset for tilstrækkeligt bevis for virkningen, da pati- enterne i undersøgelsen i forvejen var stabiliseret med en tobramycin nebulisator.
The improvements in FEV1 seen with Colobreathe were considered sufficient proof of effectiveness, considering the fact that the patients in the study were already stabilised on tobramycin nebuliser.
Forbedringerne i HbA1c efter behandlingen med saxagliptin 2,5 mg var vedvarende frem til uge 52, men antallet af patienter, som gennemførte 52 ugers behandling uden justeringer af anden antihyperglykæmisk behandling, var lavt (26 forsøgspersoner i saxagliptin-gruppen over for 34 forsøgspersoner i placebogruppen).
Improvements in HbA1c following treatment with saxagliptin 2.5 mg were sustained up to Week 52, however the number of patients who completed 52 weeks without modification of other antihyperglycaemic treatment was low (26 subjects in the saxagliptin group versus 34 subjects in the placebo group).
Forbedringerne i HbA1c, PPG og FPG efter behandling med saxagliptin 5 mg + metformin blev opretholdt frem til uge
Improvements in HbA1c, PPG, and FPG following treatment with saxagliptin 5 mg plus metformin were sustained up to
Forbedringerne i HbA1c, PPG og FPG efter behandling med saxagliptin 5 mg blev opretholdt frem til uge 76.
following treatment with saxagliptin 5 mg were sustained up to Week 76.
Forbehandling med anden antiinflammatorisk medicin kan resultere i nye eller forøgede bivirkninger, og derfor bør der være en behandlingsfri periode på mindst 24 timer, før behandling med Onsior begynder.
Pre-treatment with other anti-inflammatory medicines may result in additional or increased adverse effects and accordingly a treatment-free period with such substances should be observed for at least 24 hours before the commencement of treatment with Onsior.
Forbehandling med anden antiinflammatorisk medicin kan resultere i nye eller forøgede bivirkninger, og derfor bør der være en behandlingsfri periode på mindst 24 timer, før behandling med Onsior begynder.
Pre-treatment with other anti-inflammatory medicines may result in additional or increased adverse effects and, accordingly, a treatment-free period with such substances should be observed for at least 24 hours before the commencement of treatment with Onsior.
Forbehandling med anden betændelseshæmmende medicin kan resultere i nye eller forøgede bivirkninger, og derfor bør der være en behandlingsfri periode på mindst 24 timer, før behandling med Onsior begynder.
Pre-treatment with other anti-inflammatory medicines may result in additional or increased adverse effects and a treatment-free period with such substances should be observed for at least 24 hours before the commencement of treatment with Onsior.
Forbehandling med anden betændelseshæmmende medicin kan resultere i nye eller forøgede bivirkninger, og derfor bør der være en behandlingsfri periode på mindst 24 timer, før behandling med Onsior begynder.
Pre-treatment with other anti-inflammatory medicines may result in additional or increased adverse effects and accordingly a treatment-free period with such substances should be observed for at least 24 hours before the commencement of treatment with Onsior.
Forbehandling med andre antiinflammatoriske stoffer kan resultere i nye eller forøgede bivirkninger, og derfor bør der være en behandlingsfri periode på mindst 24 timer, før behandling med Onsior begynder.
Pre-treatment with other anti-inflammatory medicines may result in additional or increased adverse effects and accordingly a treatment-free period with such substances should be observed for at least 24 hours before the commencement of treatment with Onsior.
Forbehandling med anti-inflammatoriske substanser kan medføre yderligere eller øgede bivirkninger, og derfor skal en behandlingsfri periode med sådanne veterinærlægemidler overholdes i mindst 24 timer inden igangsætning af behandling.
Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary medicinal products should be observed for at least 24 hours before commencement of treatment.
Forbehandling med anti-inflammatoriske substanser kan medføre yderligere eller øgede negative bivirkninger, og derfor skal en behandlingsfri periode med sådanne veterinærlægemidler overholdes i mindst 24 timer inden igangsætning af behandling.
Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement of treatment.
Forbered applikatoren Fjern beskyttelseshætten af gummi.
Remove dose-divider clip
Forbered dosis:
Prepare the dose:
Forbered infusionsstedet:
Prepare the infusion site:
Forbered injektionsopløsningen: Fjern beskyttelseslåget fra hætteglasset med Luveris pulver,
Prepare the injection solution: Remove the protective cap from the Luveris powder
Forbered injektionsopløsningen: Fjern beskyttelseslåget fra hætteglasset med Luveris pulver,
Prepare the injection solution: Remove the protective cap from the Luveris powder vial, pick
Forbered injektionssprøjten
Getting ready the syringe for injection
Forbered overførslen af den rekombinante humane hyaluronidasekomponent i HyQvia ved at aftørre propperne på hætteglassene med en spritserviet, hvis det er anvist, og lade dem lufttørre (i mindst 30 sekunder).
Prepare to transfer the recombinant human hyaluronidase component of HyQvia by wiping each vial stopper with an alcohol swab, if directed and allow to air dry (at downward.
Forbered overførslen af komponenten immunglobulin 10 % i HyQvia ved at aftørre propperne på hætteglassene med en spritserviet, hvis det er anvist, og lade dem lufttørre (i mindst 30 sekunder).
Prepare to transfer the immunoglobulin 10% component of HyQvia by wiping each vial stopper with an alcohol swab, if directed and allow to air dry (at least 30 seconds).
Forbered sprøjten ved at åbne pakningen halvt fra enden nærmest den hvide stempelstang.
Prepare the syringe by partially peeling the package open from the end closest to white plunger rod.
Forbered stedet til en aseptisk fremgangsmåde.
Prepare the site for an aseptic technique.
Forberedelse
A Getting ready
Forberedelse
Method of preparation
Forberedelse
Prepare
Forberedelse af det valgte paraspinale område, hvor implantationen skal udføres
the preparation of the selected paraspinal site where the intended implantation will occur
Forberedelse af dosis
Dose Preparation
Forberedelse af en dosis af Cinryze (1000 enheder) ved at rekonstituere to hætteglas Rekonstitutionsmetode for hvert hætteglas
Preparation of one dose of Cinryze (1000 Units) by reconstituting two vials Method of reconstitution of each vial
Forberedelse af en kapsel:
Prepare capsule.
Forberedelse af Enbrel dosis til injektion ved hjælp af ‘dosisforberedelsesvejledningen’ (dosisbakkens underside)
Preparing the Enbrel dose for injection using the “dose preparation guide” (underside of the dose tray)
Forberedelse af Enbrel dosis til injektion ved hjælp af ’dosisforberedelsesvejledningen’ (dosisbakkens underside)
Preparing the Enbrel dose for injection using the “dose preparation guide” (underside of the dose tray)
Forberedelse af Humira-dosis til injektion
Preparing the Humira dose for injection
Forberedelse af implantationssted (hæmostase)
Implant field preparation (haemostasis)
Forberedelse af indsprøjtning
Getting ready to inject
Forberedelse af indsprøjtningssted
Preparing injection site
Forberedelse af indtagelse af EXUBERA
Preparing to take EXUBERA
Forberedelse af injektion
Getting started
Forberedelse af injektionen
Getting ready to inject
Forberedelse af injektionsstedet
Preparing the injection site
Forberedelse af injektionsstedet og injektion af Enbrel injektionsvæsken
Preparing the injection site and injecting the Enbrel solution
Forberedelse af Vimizim til patienter, som vejer mindre end 25 kg, bør ikke fortyndes i natriumchlorid 9 mg/ml (0,9 %)-opløsning til infusionsposer større end 100 ml.
Preparation of Vimizim for patient’s weighing less than 25 kg, should not be diluted in sodium chloride 9 mg/ml (0.9 %) solution for infusion bags larger than 100 ml.
Forberedelse og administration
Method of preparation and administration
Forberedelse og administration af Levetiracetam Hospira koncentrat til infusionsvæske, opløsning
Preparation and administration of Levetiracetam Hospira concentrate for solution for infusion
Forberedelse til administration gennem nasogastrisk sonde eller gastrostomisonde:
Preparation for nasogastric tube or gastrostomy tube administration:
FORBEREDELSE TIL DEN INTRAVENØSE ADMINISTRATION
PREPARATION FOR INTRAVENOUS ADMINISTRATION
FORBEREDELSE TIL DEN INTRAVENØSE ADMINISTRATION
PREPARATION FOR THE INTRAVENOUS ADMINISTRATION
Forberedelse til en Neupopeg-indsprøjtning
Preparing for a Neupopeg injection?
Forberedelse til Eylea-behandling
How to prepare for Eylea treatment
FORBEREDELSE TIL INDSPRØJTNING AF MEDICINEN
GETTING READY TO INJECT THE PREPARED MEDICINE
Forberedelse til injektion
Preparing the solution
Forberedelse til injektion
Setting up
Forberedelse til intravenøs administration
Preparation of the intravenous administration
Forberedelse til intravenøs administration:
Preparation for the intravenous administration
Forberedelse til Lucentis-behandling
How to prepare for Lucentis treatment
Forberedelse til Naglazyme-infusion (der skal anvendes aseptisk teknik)
Preparation of the Naglazyme infusion (aseptic technique is to be used)
Forberedelser
Getting ready
Forberingerne i SGRQ ved uge 12 var dog ikke statistisk signifikante (200109) eller klinisk relevante (200109 og 200110).
Therefore, statistical significance on this comparison cannot be inferred. placebo plus FF/VI but improvements in SGRQ at week 12 were not statistically significant (200109) or clinically relevant (200109 and 200110).
forbigåend e stigning i serum IgM3
transient increase in serum IgM levels3
forbigåend ekornea- uklarhed
transient corneal opacity
Forbigående betændelse i nerverne, der giver smerter, mathed og lammelser i armene, som ofte går videre til bryst og ansigt
Temporary inflammation of the nerves, causing pain, weakness and paralysis in the extremities and often progressing to the chest and face.
Forbigående blindhed, linsesubluksation*, natteblindhed, skotom, nedsat pupilrefleks, synsfeltdefekt, diplopi, hyfæma, miose, forskel i pupilstørrelse, hornhindeabrasion, forkammerinflammation, betændelse i øjet, konjunktival irritation
Transient blindness, lens subluxation*, night blindness, scotoma, pupillary reflex impaired, visual field defect, diplopia, hyphaema, miosis, pupils unequal, corneal abrasion, anterior chamber inflammation, eye inflammation, conjunctival irritation
Forbigående blindhed, retinale ekssudater, synsforstyrrelse, øjenirritation, øjensmerte, øjenkløe
Blindness transient, retinal exudates, visual impairment, eye irritation, eye pain, eye pruritis
Forbigående effekter på komponenter med naturlig immunitet (dvs. neutrofiler, makrofager, NK-celler)
Transient effects on components of innate immunity (i.e., neutrophils, macrophages, NK cells)
forbigående efterfulgt af induktion
tipranavir/r, followed by induction
Forbigående EKG-forandringer såsom T-taks-affladning, depression af S-T-segmentet og benigne arytmier betragtes ikke som obligatoriske indikationer for at ophøre med Myocet-behandling.
Transient ECG changes such as T-wave flattening, S-T segment depression and benign arrhythmias are not considered mandatory indications for the cessation of Myocet therapy.
Forbigående fald i antallet af blodplader, der kan resultere i blå mærker eller blødning, forbigående hævelse af kirtlerne i hals, armhule eller skridt
Temporary reduction in the number of blood particles called platelets which can result in bruising or bleeding, temporary swelling of the glands in the neck, armpit or groin.
Forbigående fald i testosteron, et mandligt kønshormon (androgen), der produceres af kroppen, primært i testiklerne.
Transient decrease of testosterone, a male hormone (androgen) made by the body, mostly produced in the testes
Forbigående fald i urinsyreniveau (0,7 mg/dl ved 12 uger og 0,5 mg/dl ved 24 uger) blev observeret efter behandling med Ilaris i komparative studier med urinsyregigt.
Increases in uric acid level (0.7 mg/dl at 12 weeks and 0.5 mg/dl at 24 weeks) were observed after Ilaris treatment in comparative trials in gouty arthritis.
Forbigående fugtighed på inder- og ydersiden af øret kan ses.
Transient wetness of the inner and outer pinna can be observed.
Forbigående hudreaktioner (bivirkninger på huden).
Cases of transient cutaneous reactions (side effects on your skin).
Forbigående hudreaktioner på påføringsstedet (hudmisfarvning, lokalt hårtab, kløe, rødmen) samt generel kløe og hårtab kan forekomme i sjældne tilfælde.
Transient skin reactions at the application site (skin discolouration, local hair loss, itching, redness) and general itching or hair loss may occur on rare occasions.
Forbigående hyperkolesterolæmi, forbigående hypertriglyceridæmi
Transient hypercholesterolaemia, transient hypertriglyceridaemia
Forbigående hævelse af hjernen.
Reversible swelling of the brain (posterior reversible encephalopathy syndrome).
Forbigående hævelse, der sædvanligvis forsvinder i løbet af 4 dage, kan forekomme på injektionsstedet.
A transient swelling which usually regresses within 4 days may appear at the injection site.
forbigående iskæmisk anfald (minislagtilfælde)
transient ischemic attack (mini stroke)
Forbigående kan milde lokale og/eller systemiske bivirkninger i forbindelse med selvinjektion observeres.
Mild local and/or systemic adverse reactions related to the injection itself may be observed transitorily.
Forbigående kløen, rødmen eller hårtab på applikationsstedet kan ses.
Transitory scratching, erythema or hair loss at the application site may occur.
Forbigående kosmetiske gener som våd pels og tørre hvide aflejringer kan forekomme på applikationsstedet og vare ved i op til syv dage.
Transient cosmetic effects such as wet hair and a white dry residue may occur at the application site and may persist up to 7 days; however, these effects are usually not noticeable after 48 hours.
Forbigående lette til moderate lokale reaktioner kan forekomme efter indgivelse af en dosis vaccine.
Slight to moderate transient local reactions may occur after the administration of one dose of vaccine.
Forbigående lokale reaktioner kan forekomme efter indgivelse af en dosis vaccine.
Transient local reactions may occur after the administration of one dose of vaccine.
Forbigående lokale reaktioner på injektionsstedet kan undertiden observeres i form af en hård, varm og nogle gange smertefuld hævelse (med en diameter på op til 10 cm).
Transient local reactions at the injection site may occur after vaccination mainly in the form of a hard, warm and sometimes painful swelling (diameter up to 10 cm).
Forbigående meningitis (hvor symptomer eller tegn er hovedpine, angst eller lysfølsomhed, nakkestivhed).
Cases of temporary meningitis (which symptoms or signs are headache, fear or intolerance of light, stiff neck).
Forbigående milde neurologiske reaktioner (f.eks. rysten, nedsat koordinationsevne) er set i meget sjældne tilfælde.
Transient mild neurological disorders (e.g. tremors, incoordination) were observed in very rare cases.
Forbigående nedstemthed og feber (>39,5oC) kan forekomme.
Transient apathy and fever (above 39.5 °C) may occur.
Forbigående nedstemthed og temperaturforhøjelse (>39,5oC) kan forekomme.
Transient apathy and hyperthermia (above 39.5 °C) may occur.
Forbigående normale symptomer efter vaccination kan også observeres, såsom: hyperthermi (der sædvanligvis varer 1 til 4 dage), apati, fordøjelsesforstyrrelser.
The transient common signs following vaccination may also be observed, such as: hyperthermia (lasting 1 to 4 days), apathy (listlessness), digestive disturbances (abdominal discomfort).